ARQ-151
Roflumilast[THERAPEUTIC_PROFILE]
Atopic Dermatitis
A small molecule inhibitor of phosphodiesterase-4
[3D_INTERACTIVE_CONFORMATION]
[CLINICAL_TRIALS_REGISTRY]
A Phase 4, Open Label Study to Assess Descriptive Classification of Pruritus Over Time With Roflumilast 0.15% Cream in Patients With Atopic Dermatitis
[INVESTIGATORS_&_FACILITY_ROSTER]
[PRIMARY_SUCCESS_ENDPOINTS]
Analysis Window: From enrollment to end of treatment at 4 weeks.
[SECONDARY_SUCCESS_ENDPOINTS]
Analysis Window: Day of baseline visit
Analysis Window: From enrollment to end of treatment at 4 weeks
Analysis Window: From enrollment to end of treatment at 4 weeks
Analysis Window: From enrollment to the end of treatment at 4 weeks
Analysis Window: From enrollment to the end of treatment at 4 weeks
Analysis Window: From enrollment to the end of treatment at 4 weeks
[COHORT_ARMS_ARCHITECTURE_BREAKDOWN]
No descriptive logs found.
[DOSING_&_INTERVENTION_SPECIFICITIES]
topically applied to the affected areas once daily
A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.3% Administered QD in Subjects With Chronic Plaque Psoriasis
[INVESTIGATORS_&_FACILITY_ROSTER]
[PRIMARY_SUCCESS_ENDPOINTS]
Analysis Window: Week 8
[SECONDARY_SUCCESS_ENDPOINTS]
Analysis Window: From start of treatment to achievement of PASI-50 or study completion/early termination (maximum duration = 124 days)
Analysis Window: Baseline (Day 1) and Week 8
Analysis Window: Baseline (Day 1) and Week 8
Analysis Window: Week 8
Analysis Window: Week 8
Analysis Window: Baseline (Day 1) and Week 2, Week 4, Week 8
Analysis Window: Baseline (Day 1) and Weeks 4 and 8
[COHORT_ARMS_ARCHITECTURE_BREAKDOWN]
Active comparator
Placebo comparator
[DOSING_&_INTERVENTION_SPECIFICITIES]
ARQ-151 0.3% cream
ARQ-151 vehicle cream
A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Subjects With Seborrheic Dermatitis
[INVESTIGATORS_&_FACILITY_ROSTER]
[PRIMARY_SUCCESS_ENDPOINTS]
Analysis Window: Week 8
[SECONDARY_SUCCESS_ENDPOINTS]
Analysis Window: Week 8
Analysis Window: Week 4
Analysis Window: Week 2
Analysis Window: Week 2
Analysis Window: Week 4
Analysis Window: Week 8
Analysis Window: Week 8
[COHORT_ARMS_ARCHITECTURE_BREAKDOWN]
Participants with seborrheic dermatitis apply roflumilast foam 0.3% once daily (QD) for 8 weeks.
Participants with seborrheic dermatitis apply vehicle foam QD for 8 weeks.
[DOSING_&_INTERVENTION_SPECIFICITIES]
Roflumilast 0.3% foam for topical application
Vehicle foam for topical application
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects With Atopic Dermatitis
[INVESTIGATORS_&_FACILITY_ROSTER]
[PRIMARY_SUCCESS_ENDPOINTS]
Analysis Window: Week 4
[SECONDARY_SUCCESS_ENDPOINTS]
Analysis Window: Week 4
Analysis Window: Week 4
Analysis Window: Week 4
Analysis Window: Week 2
Analysis Window: Week 1
Analysis Window: Week 2
Analysis Window: Week 1
[COHORT_ARMS_ARCHITECTURE_BREAKDOWN]
Participants applied roflumilast cream 0.05% qd for 4 weeks.
Participants applied vehicle cream qd for 4 weeks.
[DOSING_&_INTERVENTION_SPECIFICITIES]
Roflumilast cream for topical application.
Vehicle cream matched to roflumilast cream for topical application.
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects With Atopic Dermatitis
[INVESTIGATORS_&_FACILITY_ROSTER]
[PRIMARY_SUCCESS_ENDPOINTS]
Analysis Window: Week 4
[SECONDARY_SUCCESS_ENDPOINTS]
Analysis Window: Week 4
Analysis Window: Week 4
Analysis Window: Week 2
Analysis Window: Week 1
Analysis Window: Week 4
Analysis Window: Week 4
Analysis Window: Week 2
Analysis Window: Week 1
[COHORT_ARMS_ARCHITECTURE_BREAKDOWN]
Participants with mild to moderate AD apply roflumilast cream 0.15% QD for 4 weeks.
Participants with mild to moderate AD applied vehicle cream QD for 4 weeks.
[DOSING_&_INTERVENTION_SPECIFICITIES]
Roflumilast Cream 0.15% - Active
Cream - Vehicle
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects With Atopic Dermatitis
[INVESTIGATORS_&_FACILITY_ROSTER]
[PRIMARY_SUCCESS_ENDPOINTS]
Analysis Window: Week 4
[SECONDARY_SUCCESS_ENDPOINTS]
Analysis Window: Week 4
Analysis Window: Week 2
Analysis Window: Week 1
Analysis Window: Week 4
Analysis Window: Week 2
Analysis Window: Week 1
Analysis Window: Week 4
Analysis Window: Week 4
[COHORT_ARMS_ARCHITECTURE_BREAKDOWN]
Participants apply roflumilast cream 0.15% once daily (qd) for 4 weeks.
Participants apply vehicle cream qd for 4 weeks.
[DOSING_&_INTERVENTION_SPECIFICITIES]
Roflumilast cream 0.15% for topical application
Vehicle cream for topical application
A Randomized tRial Employing topiCal roflumilasT Foam to Treat Scalp Psoriasis (ARRECTOR)
[INVESTIGATORS_&_FACILITY_ROSTER]
[PRIMARY_SUCCESS_ENDPOINTS]
Analysis Window: Week 8
Analysis Window: Week 8
[SECONDARY_SUCCESS_ENDPOINTS]
Analysis Window: Week 2
Analysis Window: Week 4
Analysis Window: Week 8
Analysis Window: Day 1
Analysis Window: Day 3
Analysis Window: Week 1
Analysis Window: Week 8
Analysis Window: Week 8
[COHORT_ARMS_ARCHITECTURE_BREAKDOWN]
Participants with plaque psoriasis of the scalp and body applied roflumilast foam 0.3% once daily (qd) for 8 weeks.
Participants with plaque psoriasis of the scalp and body applied vehicle foam qd for 8 weeks.
[DOSING_&_INTERVENTION_SPECIFICITIES]
Roflumilast foam 0.3%
Vehicle foam matched to roflumilast 0.3% foam.
A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.3% Administered QD in Subjects With Chronic Plaque Psoriasis
[INVESTIGATORS_&_FACILITY_ROSTER]
[PRIMARY_SUCCESS_ENDPOINTS]
Analysis Window: Baseline (Day 1) and Week 8
[SECONDARY_SUCCESS_ENDPOINTS]
Analysis Window: From start of treatment to achievement of PASI-50 or study completion/early termination (maximum duration = 121 days)
Analysis Window: Baseline (Day 1) and Week 8
Analysis Window: Baseline (Day 1) and Week 8
Analysis Window: Baseline (Day 1) and Week 8
Analysis Window: Week 8
Analysis Window: Baseline (Day 1) and Weeks 2, 4, and 8
Analysis Window: Weeks 4 and 8
[COHORT_ARMS_ARCHITECTURE_BREAKDOWN]
Participants receive roflumilast cream 0.3% once daily for 8 weeks.
Participants receive vehicle cream once daily for 8 weeks.
[DOSING_&_INTERVENTION_SPECIFICITIES]
Roflumilast 0.3% cream for topical application.
Vehicle cream for topical application.
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.3% in Subjects With Chronic Plaque Psoriasis
[INVESTIGATORS_&_FACILITY_ROSTER]
[PRIMARY_SUCCESS_ENDPOINTS]
Analysis Window: 24 weeks
[SECONDARY_SUCCESS_ENDPOINTS]
Analysis Window: 24 weeks
Analysis Window: 24 weeks
Analysis Window: 24 weeks
Analysis Window: 24 weeks
Analysis Window: 24 weeks
Analysis Window: 24 weeks
Analysis Window: 24 weeks
[COHORT_ARMS_ARCHITECTURE_BREAKDOWN]
No descriptive logs found.
[DOSING_&_INTERVENTION_SPECIFICITIES]
Active treatment
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects With Atopic Dermatitis
[INVESTIGATORS_&_FACILITY_ROSTER]
[PRIMARY_SUCCESS_ENDPOINTS]
Analysis Window: Up to 52 weeks
[SECONDARY_SUCCESS_ENDPOINTS]
Analysis Window: Weeks 4, 12, 24, 36, and 52
Analysis Window: Weeks 4, 12, 24, 36, and 52
Analysis Window: Weeks 4, 12, 24, 36, and 52
Analysis Window: Weeks 4, 12, 24, 36, and 52
[COHORT_ARMS_ARCHITECTURE_BREAKDOWN]
Participants applied ARQ-151 Cream 0.05% once daily (qd) for up to 52 weeks.
[DOSING_&_INTERVENTION_SPECIFICITIES]
ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%
A Phase 2, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.3% in Adult Subjects With Chronic Plaque Psoriasis Who Have Completed Preceding Study ARQ-151-201 Phase 2 Randomized Controlled Trial (Cohort 1) and Non-ARQ-151-201 Subjects (Cohort 2)
[INVESTIGATORS_&_FACILITY_ROSTER]
[PRIMARY_SUCCESS_ENDPOINTS]
Analysis Window: Up to 52 weeks
Analysis Window: Up to 52 weeks
[SECONDARY_SUCCESS_ENDPOINTS]
Analysis Window: Weeks 12, 24, 36, and 52
Analysis Window: Up to 52 weeks
Analysis Window: Weeks 12, 24, 36, and 52
Analysis Window: Baseline and Weeks 12, 24, 36, and 52
[COHORT_ARMS_ARCHITECTURE_BREAKDOWN]
Participants applied roflumilast (ARQ-151) cream 0.3% once daily for 52 weeks
[DOSING_&_INTERVENTION_SPECIFICITIES]
Roflumilast cream 0.3% for topical application
An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)
[INVESTIGATORS_&_FACILITY_ROSTER]
[PRIMARY_SUCCESS_ENDPOINTS]
Analysis Window: Week 24
[SECONDARY_SUCCESS_ENDPOINTS]
Analysis Window: Baseline, the at weeks 4, 8, 12, 18 & 24.
[COHORT_ARMS_ARCHITECTURE_BREAKDOWN]
No descriptive logs found.
[DOSING_&_INTERVENTION_SPECIFICITIES]
Roflumilast 0.3% topical foam
A Phase 2b, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Subjects With Seborrheic Dermatitis
[INVESTIGATORS_&_FACILITY_ROSTER]
[PRIMARY_SUCCESS_ENDPOINTS]
Analysis Window: Week 8
[SECONDARY_SUCCESS_ENDPOINTS]
Analysis Window: Weeks 2 and 4
Analysis Window: Weeks 2, 4, and 8
Analysis Window: Weeks 2, 4, and 8
Analysis Window: Weeks 2, 4, and 8
Analysis Window: Weeks 2, 4, and 8
Analysis Window: Weeks 2, 4, and 8
Analysis Window: Weeks 2, 4, and 8
[COHORT_ARMS_ARCHITECTURE_BREAKDOWN]
Participants apply roflumilast foam 0.3% once daily (QD) to all areas of seborrheic dermatitis once daily for 8 weeks.
Participants apply inactive vehicle foam matched to roflumilast foam QD for 8 weeks.
[DOSING_&_INTERVENTION_SPECIFICITIES]
Roflumilast foam for topical application.
Vehicle foam for topical application.
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
[INVESTIGATORS_&_FACILITY_ROSTER]
[PRIMARY_SUCCESS_ENDPOINTS]
Analysis Window: Week 6
[SECONDARY_SUCCESS_ENDPOINTS]
Analysis Window: Weeks 4, 8, and 12
Analysis Window: Baseline (Day 1) and Weeks 4, 6, 8, and 12
Analysis Window: Baseline (Day 1) and Weeks 4, 6, 8, and 12
Analysis Window: Baseline (Day 1) and Weeks 4, 6, 8, and 12
Analysis Window: Weeks 4, 6, 8, and 12
Analysis Window: Baseline (Day 1) and Weeks 4, 6, 8, and 12
Analysis Window: Baseline (Day 1) and Weeks 4, 6, 8, and 12
Analysis Window: Baseline (Day 1) and Weeks 4, 6, 8, and 12
[COHORT_ARMS_ARCHITECTURE_BREAKDOWN]
Roflumilast cream 0.3% topically applied QD for 12 weeks.
Roflumilast cream 0.15% topically applied QD for 12 weeks.
Vehicle cream matched to roflumilast cream (containing only excipients of active cream) applied QD for 12 weeks.
[DOSING_&_INTERVENTION_SPECIFICITIES]
Applied once daily for 12 weeks
Applied once daily for 12 weeks
Applied once daily for 12 weeks
A Phase 2, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% and ARQ-151 Cream 0.15% Administered QD (Quaque Die) in Adolescent and Adult Subjects With Atopic Dermatitis
[INVESTIGATORS_&_FACILITY_ROSTER]
[PRIMARY_SUCCESS_ENDPOINTS]
Analysis Window: Baseline and Week 4
[SECONDARY_SUCCESS_ENDPOINTS]
Analysis Window: Baseline and Weeks 1, 2, and 4
Analysis Window: Baseline and Weeks 1 and 2
Analysis Window: Baseline and Weeks 1, 2, and 4
Analysis Window: Baseline and Weeks 1, 2, and 4
Analysis Window: Baseline and Weeks 1, 2, and 4
Analysis Window: Baseline and Weeks 1, 2, and 4
Analysis Window: Baseline and Weeks 1, 2, and 4
Analysis Window: Baseline and Weeks 1, 2, and 4
[COHORT_ARMS_ARCHITECTURE_BREAKDOWN]
Participants apply roflumilast cream 0.05% QD for 28 days.
Participants apply roflumilast cream 0.15% QD for 28 days.
Participants apply vehicle cream QD for 28 days.
[DOSING_&_INTERVENTION_SPECIFICITIES]
Roflumilast 0.05% cream for topical application
Roflumilast 0.15% cream for topical application
Inactive vehicle cream matched to roflumilast cream for topical application.
An Open Label, 4-Week, Phase 2, Maximal Usage Pharmacokinetics and Safety Study of ARQ-151 Cream 0.3% Administered QD in Pediatric Subjects (Ages 2 to 5 Years Old) With Plaque Psoriasis
[INVESTIGATORS_&_FACILITY_ROSTER]
[PRIMARY_SUCCESS_ENDPOINTS]
Analysis Window: Week 4
Analysis Window: Week 4
Analysis Window: Week 4
[SECONDARY_SUCCESS_ENDPOINTS]
[COHORT_ARMS_ARCHITECTURE_BREAKDOWN]
Open label study of ARQ-151 cream 0.3% applied once daily for 4 weeks
[DOSING_&_INTERVENTION_SPECIFICITIES]
ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 4 weeks
An Open Label, 4-Week, Phase 2, Maximal Usage Pharmacokinetics and Safety Study of ARQ-151 Cream 0.3% Administered QD in Pediatric Subjects (Ages 6 to 11 Years Old) With Plaque Psoriasis
[INVESTIGATORS_&_FACILITY_ROSTER]
[PRIMARY_SUCCESS_ENDPOINTS]
Analysis Window: Predose on Days 14 and 28
Analysis Window: Predose on Days 14 and 28
Analysis Window: Up to 28 days
Analysis Window: Baseline (Day 1), Day 7, and Day 14
[SECONDARY_SUCCESS_ENDPOINTS]
[COHORT_ARMS_ARCHITECTURE_BREAKDOWN]
Open label study of ARQ-151 cream 0.3% applied once daily for 4 weeks
[DOSING_&_INTERVENTION_SPECIFICITIES]
ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 4 weeks
An Open Label Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam as a Mono or add-on Therapy in the Treatment of Hidradenitis Suppurativa With Correlative Analysis.
[INVESTIGATORS_&_FACILITY_ROSTER]
[PRIMARY_SUCCESS_ENDPOINTS]
Analysis Window: Baseline, 16 weeks
[SECONDARY_SUCCESS_ENDPOINTS]
Analysis Window: Baseline, 4 months
Analysis Window: Baseline, 1 month, 4 months
Analysis Window: Baseline, 1 month, 4 months
[COHORT_ARMS_ARCHITECTURE_BREAKDOWN]
Patients must have a diagnosis of HS based upon the clinical criteria of a history of more or equal than 5 typical lesions (erythematous papules, nodules, or abscesses) in flexural sites with a recurring nature over time. Patients must be candidate for topical therapy defined by active Hurley stage I or Hurley stage II/III with active disease after an adequate trial of systemic antibiotics/hormonal/immunomodulatory or biologic therapy.
[DOSING_&_INTERVENTION_SPECIFICITIES]
Topical roflumilast is a potent phosphodiesterase 4 (PDE4) inhibitor approved for the treatment of psoriasis, seborrheic dermatitis and atopic dermatitis
A Phase 2b, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Adolescents and Adults With Scalp and Body Psoriasis
[INVESTIGATORS_&_FACILITY_ROSTER]
[PRIMARY_SUCCESS_ENDPOINTS]
Analysis Window: Week 8
[SECONDARY_SUCCESS_ENDPOINTS]
Analysis Window: Week 8
Analysis Window: Baseline and Weeks 2, 4, 8
Analysis Window: Baseline and Weeks 4 and 8
Analysis Window: Up to 8 weeks
Analysis Window: Week 8
Analysis Window: Baseline and Week 8
[COHORT_ARMS_ARCHITECTURE_BREAKDOWN]
active
placebo
[DOSING_&_INTERVENTION_SPECIFICITIES]
experimental
experimental
A Phase 2, Open Label, 4-Week, Safety Study of Roflumilast Cream 0.05% Administered Once Daily in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis
[INVESTIGATORS_&_FACILITY_ROSTER]
[PRIMARY_SUCCESS_ENDPOINTS]
Analysis Window: 4 weeks
Analysis Window: 4 weeks
Analysis Window: 4 weeks
[SECONDARY_SUCCESS_ENDPOINTS]
[COHORT_ARMS_ARCHITECTURE_BREAKDOWN]
This single study arm is open label in which ARQ-151 cream 0.05% is applied daily for 4 weeks.
[DOSING_&_INTERVENTION_SPECIFICITIES]
ARQ-151 Cream 0.05% is applied once daily for 4 weeks in infants with atopic dermatitis (eczema).
An Open Label, Phase 1, Maximal Usage Pharmacokinetics and Safety Study of ARQ-151 Cream 0.3% Administered QD in Adolescent and Adult Subjects With Chronic Plaque Psoriasis
[INVESTIGATORS_&_FACILITY_ROSTER]
[PRIMARY_SUCCESS_ENDPOINTS]
Analysis Window: 5 weeks
Analysis Window: 5 weeks
Analysis Window: 5 weeks
[SECONDARY_SUCCESS_ENDPOINTS]
Analysis Window: 5 weeks
Analysis Window: 5 weeks
Analysis Window: 5 weeks
Analysis Window: 5 weeks
Analysis Window: 5 weeks
Analysis Window: 5 weeks
[COHORT_ARMS_ARCHITECTURE_BREAKDOWN]
Open label study of ARQ-151 cream 0.3% applied once daily for 2 weeks
[DOSING_&_INTERVENTION_SPECIFICITIES]
ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 2 weeks
A Phase 1/2a Single Dose and 28-day Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream 0.5% and 0.15% in Adults With Mild to Moderate Chronic Plaque Psoriasis
[INVESTIGATORS_&_FACILITY_ROSTER]
[PRIMARY_SUCCESS_ENDPOINTS]
Analysis Window: Baseline and Week 4
[SECONDARY_SUCCESS_ENDPOINTS]
Analysis Window: Baseline and Weeks 1, 2 and 3
Analysis Window: Baseline and Weeks 1, 2, 3, and 4
Analysis Window: Baseline and Weeks 1, 2, 3, and 4
[COHORT_ARMS_ARCHITECTURE_BREAKDOWN]
Single-dose application of ARQ-151 cream 0.5% to 25 cm\^2 of psoriatic plaque(s)
ARQ-151 cream 0.5% applied daily for 28 days to all psoriatic plaques, not exceeding an application area of 5% BSA
ARQ-151 cream 0.15% applied daily for 28 days to all psoriatic plaques, not exceeding an application area of 5% BSA
Vehicle cream applied daily for 28 days to all psoriatic plaques, not exceeding an application area of 5% BSA
[DOSING_&_INTERVENTION_SPECIFICITIES]
0.5% active concentration
0.15% active concentration
Vehicle cream
An Open Label, Phase 1, Pharmacokinetics, Maximal Usage Pharmacokinetics, Safety, and Efficacy Study of ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% Administered QD in Adolescent and Pediatric Subjects With Mild to Moderate Atopic Dermatitis
[INVESTIGATORS_&_FACILITY_ROSTER]
[PRIMARY_SUCCESS_ENDPOINTS]
Analysis Window: 4 weeks
Analysis Window: 4 weeks
Analysis Window: 4 weeks
[SECONDARY_SUCCESS_ENDPOINTS]
Analysis Window: Baseline, Week 2, and Week 4
Analysis Window: Baseline, Week 2, and Week 4
Analysis Window: Baseline, Week 2, Week 4
Analysis Window: Baseline, Week 2, Week 4
Analysis Window: Baseline, Week 2, Week 4
Analysis Window: Baseline, Week 2, Week 4
Analysis Window: Baseline, Week 2, Week 4
[COHORT_ARMS_ARCHITECTURE_BREAKDOWN]
Open-label study of 0.15% or 0.05% active concentration
[DOSING_&_INTERVENTION_SPECIFICITIES]
ARQ-151 cream 0.15% applied to atopic dermatitis lesions once a day for 28 days
ARQ-151 cream 0.05% applied to atopic dermatitis lesions once a day for 28 days